JP2016516076A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516076A5
JP2016516076A5 JP2016503654A JP2016503654A JP2016516076A5 JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5 JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
insulin
chain
long
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503654A
Other languages
English (en)
Japanese (ja)
Other versions
JP6755175B2 (ja
JP2016516076A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055533 external-priority patent/WO2014147141A1/en
Publication of JP2016516076A publication Critical patent/JP2016516076A/ja
Publication of JP2016516076A5 publication Critical patent/JP2016516076A5/ja
Application granted granted Critical
Publication of JP6755175B2 publication Critical patent/JP6755175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503654A 2013-03-20 2014-03-19 インスリン投薬レジメン Active JP6755175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13160194.0 2013-03-20
EP13160194 2013-03-20
US201361804363P 2013-03-22 2013-03-22
US61/804,363 2013-03-22
PCT/EP2014/055533 WO2014147141A1 (en) 2013-03-20 2014-03-19 Insulin dosing regimen

Publications (3)

Publication Number Publication Date
JP2016516076A JP2016516076A (ja) 2016-06-02
JP2016516076A5 true JP2016516076A5 (enExample) 2017-04-27
JP6755175B2 JP6755175B2 (ja) 2020-09-16

Family

ID=47900938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503654A Active JP6755175B2 (ja) 2013-03-20 2014-03-19 インスリン投薬レジメン

Country Status (5)

Country Link
US (4) US20160296602A1 (enExample)
EP (1) EP2976096B1 (enExample)
JP (1) JP6755175B2 (enExample)
CN (1) CN105188736A (enExample)
WO (1) WO2014147141A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー/エス 新規投与レジメン
WO2018096162A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
WO2018096163A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
KR20190112747A (ko) 2017-02-01 2019-10-07 노보 노르디스크 에이/에스 응고촉진 항체
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN112313755B (zh) * 2018-06-26 2024-05-28 诺和诺德股份有限公司 为基础胰岛素滴定提供剂量推荐的系统
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
WO2020120477A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
ES2472421T3 (es) * 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
US20090074882A1 (en) * 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー/エス インスリン誘導体を含有する薬学的製剤
EP2178910B1 (en) * 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
KR20110085985A (ko) * 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
JP6249773B2 (ja) * 2010-05-10 2017-12-20 ノヴォ ノルディスク アー/エス インスリン−亜鉛錯体の調製方法
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US20130261051A1 (en) * 2010-10-27 2013-10-03 Thue Johansen Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
WO2012104339A1 (en) * 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
ES2927800T3 (es) * 2011-03-01 2022-11-11 Nutrition 21 Llc Composición de insulina y cromo para el tratamiento y la prevención de diabetes, hipoglicemia y trastornos relacionados
EP2844274B1 (en) * 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
JP2016519127A (ja) * 2013-04-30 2016-06-30 ノヴォ ノルディスク アー/エス 新規投与レジメン

Similar Documents

Publication Publication Date Title
Melson et al. Future therapies for obesity
DK1965823T3 (en) Methods of administering hypoglycemics
RU2011117645A (ru) Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
RU2419452C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ hGLP-1, ЭКСЕНДИНА-4 И ИХ АНАЛОГОВ
JP2007523881A5 (enExample)
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
RU2012123739A (ru) Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
JP2014520798A5 (enExample)
RU2014126244A (ru) Лекарственные средства, содержащие аминокислотные последовательности инсулина
JP2014501762A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2011241213A5 (enExample)
JP2011001381A (ja) Glp−1医薬組成物
EP2185178A2 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
RU2015132860A (ru) Композиции инсулинов длительного действия
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
Brandt et al. Are peptide conjugates the golden therapy against obesity?
Edmonds et al. Oral GLP-1 modulators for the treatment of diabetes
JP2015517458A5 (enExample)
RU2014147674A (ru) Фармацевтическая композиция
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus
JP2014500244A5 (enExample)
JP6049625B2 (ja) 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
Shibata et al. Effect of glucagon, glicentin, glucagon-like peptide-1 and-2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch
Lee et al. Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact